PET in women with high risk for breast or ovarian cancer

Einat Even-Sapir, Moshe Inbar

Research output: Contribution to journalComment/debate

Abstract

Data on the use of PET in women with genetic or familial high-risk for breast or ovarian cancer are scarce. Open issues include the complementary use of dedicated breast-PET scanners in patients at high-risk for breast cancer, the relation between pathological characteristics of cancer diagnosed in BRCA carriers and 18F-fluorodeoxyglucose (18F-FDG)-avidity, and the predictive value of PET in patients at high-risk for ovarian cancer presenting with a pelvic mass or potential chemical markers. Therefore, the use of PET in high-risk patients with unproven malignant disease needs to be investigated in well designed clinical trials. Once breast or ovarian cancer is diagnosed, indications for 18F-FDG-PET or PET-CT imaging are similar for high-risk patients and patients with sporadic cancer. However, PET can provide data that are beyond tumour detection per se. Future directions of PET in high-risk patients might include monitoring the response of BRCA carriers to new treatments such as poly-ADP ribose polymerase (PARP) inhibitors, personalisation of treatment, and the use of new PET tracers to investigate the tissue changes related to increased risk for breast and ovarian cancer.

Original languageEnglish
Pages (from-to)899-905
Number of pages7
JournalThe Lancet Oncology
Volume11
Issue number9
DOIs
StatePublished - Sep 2010

Fingerprint

Dive into the research topics of 'PET in women with high risk for breast or ovarian cancer'. Together they form a unique fingerprint.

Cite this